Editorial · 31 Aug 2023
Conference proceedingPublished 30 Dec 2022
Knowledge Translation for Implementation of Point-of-Care Technology (POCT) in Breast Cancer Survivors in Africa: Descriptive study
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Obesity and mediators of inflammation have been identified as the most important risk and predictive factors in postmenopausal breast cancer survivors (BCS) using aromatase inhibitors (AIs). Data is lacking on the effects of AIs on clinical, biomedical and genetic markers among postmenopausal BC women in the African settings. Purpose: To assess the feasibility of HyBeacon probe genotyping adjunctive to standard care for timely prediction and diagnosis of AI-associated adverse events in breast cancer survivors in Africa. Methods: Cross sectional study was conducted to assess the knowledge of POCT among six African countries using online survey and telephonically contacted. Incremental cost effectiveness ratio (ICER) was calculated, using diagnostic accuracy study. This was based on mathematical modeling. Results: One hundred twenty-six participants were considered for analysis (mean age = 61 years; SD = 7.11 years; 95%CI: 60-62 years). Comparison of genotyping from HyBeacon probe technology to Sanger sequencing showed that sensitivity was reported at 99% (95% CI: 94.55% to 99.97%), specificity at 89.44% (95% CI: 87.25 to 91.38%), PPV at 51% (95%: 43.77 to 58.26%), and NPV at 99.88% (95% CI: 99.31 to 100.00%). Based on the mathematical model, the assumptions revealed that ICER was R7 044.55. Conclusion:HyBeacon®probe genotyping for AI-associated adverse events is cost effective in Africa. The barriers for implementation of POCT application among six African countries for diagnosis of breast cancer included governance issues, insufficient awareness and insufficient trainings, lack of lab equipment’s, insufficient funding’s and ethical guidance issues for conducting genetic testing’s in African context. Keywords Unified fever definition; Blood flow; Temperature; Hyperthermia; Hypothermia; Heat energy
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Molecular Enzymology and Drug Targets.
Editorial · 31 Aug 2023
Beyond the Norm: Unraveling Non-competitive Inhibition in Enzyme Kinetics and Drug Development
Editorial · 31 Aug 2023
Targeting the Achilles Heel: Cancer Drug Targets for Precision Therapies
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMolecular Enzymology and Drug Targets
- SubjectBiochemistry & Biotechnology
- SubjectGenetics & Molecular Biology
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Jean Paul Milambo”
- BylineArticles whose byline prints “James Ndirangu”
- BylineArticles whose byline prints “Peter Nyasulu”
- BylineArticles whose byline prints “David Niyukuri”
- BylineArticles whose byline prints “John Akudugu”
